ProShare Advisors
CRBU icon

ProShare Advisors’s Caribou Biosciences CRBU Stock Holding History

ProShare Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,810
Closed -$16.3K – 2098
2025
Q1 		$16.3K Sell
17,810
-5,360
-23% -$6.97K ﹤0.01% 2046
2024
Q4 		$36.8K Buy
23,170
+2,284
+11% +$4.59K ﹤0.01% 2217
2024
Q3 		$40.9K Buy
20,886
+4,345
+26% +$8.9K ﹤0.01% 1997
2024
Q2 		$27.1K Sell
16,541
-4,366
-21% -$14K ﹤0.01% 1793
2024
Q1 		$107K Buy
20,907
+1,704
+9% +$10.5K ﹤0.01% 1812
2023
Q4 		$110K Buy
19,203
+3,728
+24% +$18.4K ﹤0.01% 1769
2023
Q3 		$74K Buy
15,475
+4,107
+36% +$25.5K ﹤0.01% 1679
2023
Q2 		$48.3K Buy
11,368
+538
+5% +$2.42K ﹤0.01% 1776
2023
Q1 		$57.5K Sell
10,830
-1,433
-12% -$8.93K ﹤0.01% 1658
2022
Q4 		$77K Buy
12,263
+963
+9% +$8.57K ﹤0.01% 1695
2022
Q3 		$119K Buy
11,300
+507
+5% +$4.72K ﹤0.01% 1525
2022
Q2 		$59K Sell
10,793
-4,973
-32% -$38K ﹤0.01% 1682
2022
Q1 		$145K Buy
15,766
+2,856
+22% +$30.1K ﹤0.01% 1962
2021
Q4 		$195K Buy
+12,910
New +$251K ﹤0.01% 2043

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's CRBU Position: Q2 2025 in Review

ProShare Advisors sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 17,810 shares — an estimated $16.3K sold.

ProShare Advisors first reported a position in CRBU in Q4 2021 and held it in 14 quarters. The position peaked at $195K in Q4 2021. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • ProShare Advisors reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 17,810 Caribou Biosciences shares in Q2 2025, an estimated $16.3K.
  • ProShare Advisors first reported a position in Caribou Biosciences in Q4 2021 and held it in 14 quarters.
  • ProShare Advisors's Caribou Biosciences position peaked at $195K in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.